洛铂联合替吉奥治疗晚期胃癌的疗效及循环肿瘤细胞的预测价值
该回顾性研究纳入64例接受洛铂联合替吉奥化疗的晚期胃癌患者,分析疗效、安全性及循环肿瘤细胞(CTC)的预测作用。结果显示客观缓解率37.5%、疾病控制率65.6%,中位无进展生存期10.8个月、总生存期16.1个月,CTC水平与疗效及预后相关。
要点
- 洛铂联合替吉奥在晚期胃癌中显示 promising 抗肿瘤活性且安全性可控。
- 化疗前CTC≥2个与更差疾病控制率和总生存期显著相关。
- 化疗后CTC≥2个与更差客观缓解率、无进展生存期和总生存期显著相关。
核心结论
- 洛铂联合替吉奥治疗晚期胃癌安全有效,CTC可作为评估化疗疗效和预测预后的生物标志物。
研究设计与样本
- 回顾性分析2014年1月至2015年2月聊城市人民医院64例接受洛铂联合替吉奥化疗的晚期胃癌患者。
主要发现
- 64例患者均完成2个周期化疗,部分缓解24例(37.5%),疾病稳定18例(28.1%),疾病进展22例(34.4%),客观缓解率37.5%,疾病控制率65.6%。
- 全组中位无进展生存期10.8个月(95%CI 7.1-12.0),中位总生存期16.1个月(95%CI 12.4-18.8)。
- 化疗前CTC≥2个与CTC<2个患者的总生存期分别为10.5个月和17.2个月(P<0.001),疾病控制率分别为47.2%和89.3%(P=0.008)。
- 化疗2周期后CTC≥2个与CTC<2个患者的客观缓解率分别为16.7%和50.0%(P=0.007),中位无进展生存期分别为6.6个月和8.9个月(P<0.001),中位总生存期分别为8.4个月和15.0个月(P=0.002)。
- 治疗前后CTC均较低或治疗后CTC降低者中位无进展生存期和总生存期较长,持续高水平或上升者较短。
关键数值与推荐
- 不良反应以胃肠道反应及骨髓抑制为主,绝大多数为Ⅰ、Ⅱ级,无患者因不良反应终止化疗。
临床怎么用
- 在晚期胃癌接受洛铂联合替吉奥化疗时,可动态监测CTC水平以辅助评估疗效和预后。
局限性
- 回顾性研究,样本量64例,来自单中心,结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the efficacy and safety of lobaplatin (LBP) plus S-1 for advanced gastric cancer (AGC) and determine the potential role of circulating tumor cells (CTC) for predicting the therapeutic response and prognosis. Methods: From January 2014 to February 2015, 64 consecutive patients with AGC received lobaplatin plus S-1 chemotherapy in Liaocheng People's Hospital. The clinical features, clinical response, adverse effects, prognosis and CTC pre- and post-treatment were retrospectively analyzed. The correlation between CTC and patients' disease control rate (DCR), objective response rate (ORR), progression free survival (PFS) as well as overall survival (OS) were investigated. Results: All 64 patients completed 2 cycles of chemotherapy.The number of patients who achieved complete regression, partial regression, stable and progression were 0, 24 (37.5%), 18 (28.1%) and 22 (34.4%), respectively. ORR was 37.5% and DCR was 65.6%. The median PFS was 10.8 months(95%CI 7.1-12.0) and the median OS was 16.1 months(95%CI 12.4-18.8). The ORR and PFS were not significantly different between patients with baseline CTC≥2 and CTC<2 (25.0% vs 53.6%, P=0.150; 6.2 months vs 7.5 months, P=0.780), while the DCR and OS were significantly different (45.9% vs 90.0%, P=0.008; 10.5 months vs 17.2 months, P<0.001). After 2 cycles of chemotherapy, the ORR and DCR in patients with CTC≥2 were 16.7% and 45.9%, respectively, which were significantly lower than those observed in patients with CTC<2 (50.0% and 90.0%, respectively). The former also had shorter median PFS and OS (6.6 months vs 8.9 months, 8.4 months vs 15.0 months, respectively). Patients with persistently CTC<2 or those exhibiting an conversion to CTC<2 following chemotherapy had an improved PFS and OS, while patients with persistently CTC≥2 or those exhibiting an conversion to CTC≥2 following therapy had shorter PFS and OS.The most frequent adverse effects were grade 1 or 2 gastrointestinal discomfort and myelosuppression. No patients discontinued chemotherapy because of adverse events. Conclusions: Lobaplatin plus S-1 had manageable safety profile and promising antitumor activity in patients with AGC. CTC could be used as a biomarker in evaluating therapeutic response and predicting their prognosis. 目的: 研究洛铂(LBP)联合替吉奥(S-1)治疗进展期胃癌(AGC)的疗效及血清循环肿瘤细胞(CTC)在评估化疗疗效和预测预后方面的作用。 方法: 收集2014年1月至2015年2月聊城市人民医院收治的64例行LBP联合S-1化疗AGC患者的资料,记录其临床特点、化疗疗效、不良反应、生存时间、化疗前后CTC水平等,并分析化疗前后CTC水平与疾病控制率(DCR)、客观缓解率(ORR)、无进展生存时间(PFS)和总生存时间(OS)的关系。 结果: 64例患者均完成2个周期化疗。部分缓解24例(37.5%),疾病稳定18例(28.1%),疾病进展22例(34.4%),客观缓解率(ORR)为37.5%,疾病控制率(DCR)为65.6%。全组患者的中位PFS为10.8个月(95%CI为7.1~12.0个月),中位OS为16.1个月(95%CI为12.4~18.8个月)。化疗前,CTC≥2个和CTC<2个患者的ORR分别为25.0%和53.6%,差异无统计学意义(P=0.150);DCR分别为47.2%和89.3%,差异有统计学意义(P=0.008)。化疗2个周期后,CTC≥2个和CTC<2个患者的ORR分别为16.7%和50.0%,差异有统计学意义(P=0.007);DCR分别为45.9%和90.0%,差异有统计学意义(P=0.015)。化疗前,CTC≥2个患者的中位PFS为6.2个月,CTC<2个患者的中位PFS为7.5个月,差异无统计学意义(P=0.780);CTC≥2个患者的中位OS为10.5个月,CTC<2个患者的中位OS为17.2个月,差异有统计学意义(P<0.001)。化疗2个周期后,CTC≥2个患者的中位PFS为6.6个月,明显短于CTC<2个患者的中位PFS(8.9个月,P<0.001);CTC≥2个患者的中位OS为8.4个月,明显短于CTC<2个患者的中位OS(15.0个月,P=0.002)。治疗前后CTC均较低或治疗后CTC降低者的中位PFS和中位OS较长,而治疗前后CTC均处于高水平或治疗后CTC上升者的中位PFS和中位OS则较短。化疗不良反应以胃肠道反应及骨髓抑制为主,绝大多数为Ⅰ、Ⅱ级反应,全组无一例患者因不良反应结束化疗。 结论: LBP联合S-1治疗AGC安全、有效,且CTC可用于评估化疗的疗效和预后。.
引用
- Feng Q, Zhao JR, Zhang AX, et al. [Efficacy of lobaplatin plus S-1 and the predictive value of circulating tumor cell in patients with advanced gastric cancer]. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 30293397. doi:10.3760/cma.j.issn.0253-3766.2018.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。